ProMIS Neurosciences Inc

For the period ended Mar 31, 2024. Filed May 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 14, 2024

PMN$4.05-2.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets


· · March 31, · · December 31, ·
· 2024 · 2023 ·
Assets
Current assets:
Cash	$2,496,973	$12,598,146
Short-term investments	32,358	32,358
Prepaid expenses and other current assets	1,018,969	988,641
Total current assets	3,548,300	13,619,145
Total assets	$3,548,300	$13,619,145
Liabilities and Shareholders' Equity (Deficit)
Current liabilities:
Accounts payable	$1,403,592	$7,843,136
Accrued liabilities	1,242,322	1,506,526
Total current liabilities	2,645,914	9,349,662
Share-based compensation liability	716,969	422,002
Warrant liability	108,318	94,185
Total liabilities	3,471,201	9,865,849

Commitments and contingencies
Shareholders' equity (deficit):
Series 2 Convertible Preferred Shares, no par value, unlimited shares authorized, 1,166,667 shares issued and outstanding as of March 31, 2024 and December 31, 2023	—	—
Common shares, no par value, unlimited shares authorized, 18,961,116 and 18,885,254 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	—	—
Additional paid-in capital	97,549,317	97,590,426
Accumulated other comprehensive loss	(371,184)	(371,184)
Accumulated deficit	(97,101,034)	(93,465,946)
Total shareholders' equity (deficit)	77,099	3,753,296
Total liabilities and shareholders' equity (deficit)	$3,548,300	$13,619,145

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.